European Journal of Gastroenterology & Hepatology最新文献

{"title":"Cardiovascular events and incident diabetes in 220 patients with MASLD according to basal liver fibrosis: a 10-year follow-up historic cohort.","authors":"Cinthia Choque Vargas, Francisco Cáceres, Graciela Landeira, Soledad Perez, Laura Marchi, Gabriela Ruffillo, Silvina Tevez, Miguel Puga-Tejada, Eduardo Fassio","doi":"10.1097/MEG.0000000000002943","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002943","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study is to analyze association between liver fibrosis with CVE, incident diabetes, and cirrhosis complications.</p><p><strong>Methods: </strong>Historic cohort of biopsy-proven MASLD patients, divided into two groups: F0-F2 vs F3-F4 fibrosis. Baseline data included metabolic traits and liver function tests. Patients were contacted and scheduled for laboratory analysis and elastography. Endpoints were (a) CVE, defined as any of acute myocardial infarction, coronary stenting, ischemic cardiopathy, and stroke; (b) incident diabetes; (c) cirrhosis complications. Baseline data were collected at the time of liver biopsy, while follow-up data were recovered through personal interview or medical records. A stepwise logistic regression determined predictive variables for each endpoint.</p><p><strong>Results: </strong>Study population included 220 patients with median age 53 years, and 145 were women; baseline fibrosis was F0-F2 in 165 patients and F3-F4 in 55 patients; median follow-up was 9.9 years. A higher percentage of F3-F4 patients had CVE (29.4%) than F0-F2 ones (13.1%) (hazard ratio 2.42; 95% CI: 1.26-4.6; P = 0.008). Incident diabetes occurred in 53.3% of F3-F4 and 20.2% of F0-F2 cohort (hazard ratio 3.04; 95% CI: 1.99-4.86; P < 0.001); cirrhosis complications occurred in 9/55 F3-F4 patients and in 1/165 F0-F2 ones (hazard ratio 26.3; 95% CI: 3.3-208.3; P = 0.002). Multivariate analysis confirmed liver fibrosis as an independent predictor of incident diabetes and cirrhosis complications. CVE were associated with baseline diabetes and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio.</p><p><strong>Conclusion: </strong>In a cohort of 220 MASLD patients followed for 9.9 years, baseline F3-F4 was associated with incident diabetes and cirrhosis complications. AST/ALT ratio and diabetes were associated with CVE.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of oral antibiotic cocktail in medically refractory paediatric acute severe colitis: a case series.","authors":"Manal Morgan, Benjamin Loel, Ray Lang, Claire Reilly, Fariha Balouch, Chris Burgess, Nikhil Thapar, Peter Lewindon","doi":"10.1097/MEG.0000000000002950","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002950","url":null,"abstract":"<p><strong>Objective: </strong>Paediatric acute severe colitis (ASC) is a life-threatening gastroenterological emergency and a predictor of poor long-term inflammatory bowel disease outcomes. We report our experience with oral antibiotic combination therapy as rescue therapy for children with ASC failing to respond to conventional medical therapy (CMT).</p><p><strong>Methods: </strong>We analysed data of children admitted with ASC between January 2020 and January 2023 who failed steroids and infliximab and received the oral antibiotic combination therapy (vancomycin, amoxicillin, metronidazole and doxycycline). Treatments and responses including Paediatric Ulcerative Colitis Activity Index (PUCAI), biochemical markers, intestinal ultrasound (IUS) and colectomy rates (acute and deferred) were collated.</p><p><strong>Results: </strong>Oral antibiotic combination therapy was prescribed in 12 episodes of ASC in 11 children following failure of CMT. Improvements were seen in PUCAI (mean difference = -27.86, 95% confidence interval = -43.43 to -12.28, P < 0.001), albumin (mean: 29.5-33.6) and CRP (mean: 12-4), as well as in IUS (bowel wall thickening, extent of involvement or vascularity in five of seven). Five of 11 children were colectomy free at a maximum follow-up of 24 months. Three children had acute colectomy during index admission and three underwent deferred colectomy at a mean of 4 months.</p><p><strong>Conclusion: </strong>Oral antibiotic combination therapy shows promise in deferring and, in some cases, averting the need for acute colectomy in medically refractory ASC. This notable finding warrants confirmation in larger studies.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of gastroesophageal reflux disease in adult coeliac disease at diagnosis and during follow-up: a 20-year retrospective study.","authors":"Stiliano Maimaris, Lorenza Mangili, Paolo Minerba, Giulio Massetti, Chiara Scarcella, Annalisa Schiepatti, Federico Biagi","doi":"10.1097/MEG.0000000000002953","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002953","url":null,"abstract":"<p><strong>Objective: </strong>Gastroesophageal reflux disease (GORD) is commonly reported in coeliac disease (CD). However, long-term data on GORD in coeliac patients on a gluten-free diet (GFD) are lacking. We aimed to evaluate the prevalence of GORD and endoscopic lesions in coeliac patients at diagnosis and throughout follow-up.</p><p><strong>Methods: </strong>Adult patients directly diagnosed with CD from January 2000 to October 2021 who underwent follow-up duodenal biopsy were enrolled. Clinical data were retrospectively collected and analysed.</p><p><strong>Results: </strong>A total of 197 patients (141 F, mean age at diagnosis 36 ± 13 years) were studied. At diagnosis, 33/197 (16.8%) had reflux symptoms and 12/197 (6.1%) had oesophagitis. Only 7/33 (21.9%) still had reflux symptoms at follow-up duodenal biopsy (median 16 months, interquartile range: 13-20). Conversely, 7/164 (4.3%) patients without GORD at diagnosis developed reflux symptoms after starting a GFD. Overall, GORD was significantly more common at diagnosis of CD than at follow-up duodenal biopsy (P < 0.01), where only five had oesophagitis. GFD adherence was good in 90.4% and duodenal biopsy showed recovery of villous atrophy in 83.8% of patients. Neither GFD adherence (P = 1.00) nor mucosal recovery (P = 0.13) were related to GORD at follow-up biopsy. During follow-up (median 111 months), 41/197 patients (20.8%) reported ongoing reflux symptoms, more commonly in those with GORD at CD diagnosis (42.4% vs. 16.5%, P < 0.001).</p><p><strong>Conclusion: </strong>GORD is common in coeliac patients at diagnosis and improves in the large majority of patients after starting a GFD. However, a minority of patients develop GORD after starting a GFD, and ongoing reflux symptoms are common during long-term follow-up in coeliac patients.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma microRNA-30a expression in patients with chronic hepatitis B and its application value in the assessment of the severity of liver fibrosis.","authors":"Qiufeng He, Zhili Chen, Yang Deng, Chuangjie Mao","doi":"10.1097/MEG.0000000000002918","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002918","url":null,"abstract":"<p><strong>Objective: </strong>The severity of liver fibrosis (LF) in chronic hepatitis B (CHB) affects the outcome and treatment. We probed plasma miR-30a expression in CHB patients and its value in assessing LF severity.</p><p><strong>Methods: </strong>This retrospective study included 160 CHB patients and another 98 controls. Levels of lipid parameters, liver function parameters, hemoglobin, and alpha-fetoprotein were quantified by ELISA and chemiluminescence immunoassay. White blood cell, platelet, and red blood cell counts were determined using an automatic hematology analyzer. Fibrosis index based on four factors (FIB-4) was calculated. miR-30a level was determined, followed by the analysis of correlations of miR-30a expression with LF classification or with FIB-4 in CHB patients. The diagnostic value of plasma miR-30a for mild-to-moderate and severe LF in CHB patients was analyzed by receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>Plasma miR-30a was poorly expressed in CHB patients and decreased dependently with LF aggravation. miR-30a was negatively interrelated with LF classification and FIB-4. Plasma miR-30a had high diagnostic value for mild-to-moderate LF in CHB patients [area under the ROC curve (AUC) = 0.775, cutoff value = 0.71, 95% confidence interval (CI) = 0.685-0.849]. Plasma miR-30a had high diagnostic value for severe LF in CHB patients (AUC = 0.873, cutoff value = 0.49, 95% CI = 0.804-0.924).</p><p><strong>Conclusion: </strong>Plasma miR-30a was weakly expressed in CHB patients. miR-30a expression was negatively correlated with LF severity in CHB patients. miR-30a had high diagnostic value for mild-to-moderate and severe LF in CHB patients. miR-30a might serve as a promising target for LF treatment.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The usefulness of serum leucine-rich alpha-2 glycoprotein as a novel biomarker in monitoring inflammatory bowel disease: a systematic review and meta-analysis.","authors":"Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Behrad Saeedian, Tannaz Bagheri, Abdulrahman Ismaiel, Satohiro Matsumoto, Nastaran Babajani","doi":"10.1097/MEG.0000000000002952","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002952","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD) is a condition of unknown origin. It does not have a definite cure and its response to various treatments can be evaluated based on symptom-based measures, invasive procedures, or biomarker levels, highlighting the need for an accurate biomarker. Since C-reactive protein (CRP) and fecal calprotectin have their shortcomings, the need for a novel biomarker remains critical. Systematic searches of PubMed, Scopus, Web of Science, and Embase were performed In January 2024. PROSPERO number is CRD42024507383. We assessed the accuracy of leucine-rich alpha-2 glycoprotein (LRG) in identifying disease activity among patients with IBD using a bivariate diagnostic random-effects model. Fourteen studies involving 1794 individuals conducted in Japan were selected for our systematic review. The sensitivity and specificity of LRG levels for detecting disease activity were analyzed in patients with IBD and in two subgroups (ulcerative colitis and Crohn's disease). The synthesized sensitivity and specificity were 75.4% [95% confidence interval (CI), 68.9-80.9%] and 77.3% (95% CI, 69.9-83.2%), respectively, in patients with IBD, 73.1% (95% CI, 62.7-81.5%) and 81.9% (95% CI, 73.9-87.8%), respectively, in patients with CD, and the secondary analysis of the ulcerative colitis subgroup showed a pooled sensitivity and specificity of 72.8 and 59.7%, respectively. Our systematic review and meta-analysis demonstrated that LRG could be useful in detecting IBD activity. It is superior for detecting disease activity, especially in patients with normal CRP levels. The LRG was more accurate in monitoring disease activity in patients with CD than in patients with IBD.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The causes, and impact, of colonoscopic perforation for endoscopists: lessons from a qualitative interview study.","authors":"Edmund Derbyshire, Sally Brown, Sir Pali Hungin, Christina Dobson, Matthew D Rutter","doi":"10.1097/MEG.0000000000002945","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002945","url":null,"abstract":"<p><strong>Introduction: </strong>Safety and the avoidance of adverse events are crucial in patient care. A number of explanatory variables for the serious adverse event of colonoscopic perforation have been identified; however, the context in which perforation occurs has largely been overlooked, as too has the subsequent impact on the colonoscopist. This study examined the human and environmental factors associated with colonoscopic perforations, along with colonoscopists' reactions to these, with a view to informing strategies for safer practice and clinician support.</p><p><strong>Methods: </strong>This qualitative study explored the experiences of colonoscopists who reported a previous colonoscopic perforation. Semi-structured interviews were undertaken with 11 colonoscopists, recruited through professional networks. Interviews were recorded and transcribed and analysed using a framework approach.</p><p><strong>Results: </strong>Human and environmental factors contributing to perforation included colonoscopist fatigue, time pressure and equipment failure. Four distinct stages were identified in colonoscopists' reactions to perforation: 'The Perforation Realisation' comprising a range of strong and powerful emotions; 'The Consequences' involving feelings of personal responsibility, self-blame, fear of repercussion and vulnerability; 'Acceptance and Refocus' comprising a period of coming to terms with the perforation; and finally 'Reflection and Learning' where the colonoscopist reflected on the case and applied learning to their future practice.</p><p><strong>Conclusion: </strong>This study examines colonoscopists' personal experiences of perforations. It identifies the stages that colonoscopists experience after causing a perforation, and some of the broader contextual factors that can lead to these potentially preventable adverse events. The data suggest the need for greater emotional and pastoral support for endoscopists when such events occur.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrointestinal bleeding in long-distance runners: a systematic review.","authors":"Miroslav Vujasinovic, Masami Omae, Nikola Panic, Eva Fjellgren, Nina Bloch, Zdenko Kikec, Marko Grasselli, Greger Lindberg, Johannes-Matthias Löhr, Francisco Baldaque-Silva","doi":"10.1097/MEG.0000000000002931","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002931","url":null,"abstract":"<p><strong>Objective: </strong>Long-distance running has become increasingly popular in recent decades all over the world. Besides musculoskeletal injuries, gastrointestinal (GI) complaints are also very common in athletes.</p><p><strong>Methods: </strong>A systematic search limited to articles in the English language was performed to identify studies on GI bleeding in long-distance runners. The primary outcomes were the incidence and outcome of overt and occult GI bleeding in long-distance runners.</p><p><strong>Results: </strong>A total of 51 articles were included in the final analysis. We found 22 articles reporting 36 cases of overt GI bleeding in long-distance runners. GI bleeding has been reported as a cause of death in one patient. Conservative treatment was used in most of the cases, and surgery was performed on four patients. We found 22 articles (759 runners included) related to occult GI bleeding and seven articles (6671 runners included) related to occult GI bleeding, based on questionnaire-based surveys.</p><p><strong>Conclusion: </strong>Gastrointestinal bleeding may occur in long-distance runners, highlighting the need for further investigation into this issue. It is essential to conduct well-designed prospective studies on this topic, preferably using noninvasive diagnostic methods, such as capsule panendoscopy, to improve our understanding and management of this condition.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global trends and disparities in gallbladder and biliary tract cancers: insights from the global burden of disease study 2021.","authors":"Zhifeng Zhao, Haoyu Wu, Jun Han, Kai Jiang","doi":"10.1097/MEG.0000000000002947","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002947","url":null,"abstract":"<p><strong>Background: </strong>Gallbladder and biliary tract cancers (GBC and BTC) are highly malignant, with poor prognoses and substantial regional variability in the disease burden. Although advances in medical science have improved outcomes in high-income regions, low- and middle-income regions continue to face rising incidence and mortality rates owing to delayed detection and treatment. Understanding the global trends and risk factors of GBC and BTC is essential for targeted interventions to reduce disease burden.</p><p><strong>Methods: </strong>A retrospective analysis of GBC and BTC was conducted using the 2021 Global Burden of Disease study. Data from 204 countries and territories between 1990 and 2021 were analyzed for incidence, mortality, and disability-adjusted life years stratified by age, sex, and sociodemographic index (SDI). Trends were quantified using age-standardized rates and estimated annual percentage changes.</p><p><strong>Results: </strong>In 2021, 216,768 new cases and 171,961 deaths were reported globally, with age-standardized incidence and mortality rates of 2.6 and 2.0 per 100,000, respectively. The high-income Asia-Pacific and Latin American regions exhibited the highest disease burdens. While global age-standardized rates declined estimated annual percentage changes for incidence: -0.44; mortality: -0.97), low-SDI regions experienced increases. High BMI emerged as the leading risk factor, contributing to 12% of the disability-adjusted life years. Projections indicate a stable incidence but rising mortality by 2036.</p><p><strong>Conclusion: </strong>Although the global age-standardized rates of GBC and BTC are decreasing, disparities persist, with low-SDI regions experiencing increasing burdens. Targeted interventions addressing modifiable risk factors such as obesity, along with improved healthcare infrastructure and early detection, are critical for mitigating this global health challenge.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sterile systemic inflammation reaction associated with 90-day mortality in patients with HBV-related acute-on-chronic liver failure.","authors":"Jing Chen, Xiaoyan Liu, Chongdan Guan, Yuhui Peng, Chen Li, Lilong Yan, Peng Ning, Jinhua Hu, Haibin Su","doi":"10.1097/MEG.0000000000002937","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002937","url":null,"abstract":"<p><strong>Background: </strong>Acute-on-chronic liver failure (ACLF) represents the terminal and most lethal phase of acute decompensated cirrhosis. Systemic inflammation plays a critical role in the pathogenesis of ACLF. Systemic inflammation reaction syndrome (SIRS) is a marker of ongoing inflammation. Therefore, we aim to evaluate the relationship of sterile SIRS with hepatitis B virus (HBV)-related ACLF (HBV-ACLF).</p><p><strong>Methods: </strong>HBV-ACLF patients with sterile SIRS who were hospitalized between December 2016 and December 2018 were retrospectively analyzed. All patients were followed up until 90 days. Risk factors associated with 90-day mortality and sterile SIRS development were assessed.</p><p><strong>Results: </strong>Among 151 HBV-ACLF patients without infection, 37 patients (24.5%) presented with or developed sterile SIRS. During the 90-day follow-up, 23 of the 37 patients with sterile SIRS died (62.2%), compared to 40 patients without sterile SIRS (35.1%, P = 0.004). Univariate analysis showed that age, total bilirubin (TBIL), international normalized ratio, ammonia, presence of sterile SIRS, model for end-stage liver disease score, presence of complications, and organ failures were associated with 90-day mortality. In multivariate analyses, the presence of sterile SIRS was an independent risk factor for 90-day mortality. Among SIRS components, heart rate (HR) was the most frequently met criterion (56 patients, 37.09%). Patients who met the HR or temperature criterion had lower 90-day survival rate than those who did not (46.4 vs 65.3%, P = 0.020; 16.7 vs 60.0%, P = 0.020).</p><p><strong>Conclusion: </strong>The presence of sterile SIRS in HBV-ACLF patients was closely associated with prognosis.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of serum HBV RNA on HBeAg seroconversion in treated chronic hepatitis B patients.","authors":"Ting Liu, Yuru Shi, Jing Wu, Linghan Qin, Yingjie Qi","doi":"10.1097/MEG.0000000000002946","DOIUrl":"https://doi.org/10.1097/MEG.0000000000002946","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the predictive value of serum hepatitis B virus (HBV) RNA on HBeAg seroconversion in treated chronic hepatitis B (CHB) patients.</p><p><strong>Methods: </strong>Sixty-four HBeAg-positive CHB patients were selected. They were divided into HBeAg seroconversion group including 11 cases and HBeAg non-seroconversion group including 53 cases. HBV RNA levels and other laboratory results were measured at baseline and week 12, 24, 48, 72 during treatment in both groups. The predictive value of HBV RNA level for the seroconversion of HBeAg in patients treated for hepatitis B was analyzed.</p><p><strong>Results: </strong>Significant differences existed in serum HBV DNA and HBV RNA levels between the two groups at baseline while there was no significant difference in HBsAg. The correlation between HBV RNA and HBV DNA was significantly high (r = 0.707, P < 0.05), while the correlation between HBV DNA and HBsAg (r = 0.474, P < 0.05) or HBV RNA and HBsAg was poor (r = 0.372, P < 0.05). Patients with younger age and higher HBV RNA levels at baseline and week 24 were less likely to have HBeAg seroconversion. HBV RNA was better than HBV DNA and HBsAg in predicting HBeAg seroconversion whether at baseline or week 12 and week 24. The area under the curve of HBV RNA level at 24th week was the highest, which was 0.942, and the cutoff value was 4.145 log10 copies/ml.</p><p><strong>Conclusion: </strong>HBV RNA level may be a suitable serum marker to predict whether HBeAg seroconversion can occur. CHB patients with serum HBV RNA level lower than 4.145 log10 copies/ml at week 24 were more likely to achieve HBeAg seroconversion.</p>","PeriodicalId":11999,"journal":{"name":"European Journal of Gastroenterology & Hepatology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}